Thermo Fisher Scientific Inc. (TMO) — closed signal from January 14, 2026
Partial Published before the outcome was known, scored automatically when the window closed on April 14, 2026.
Predicted vs. what happened
What happened
Reached 31% of the predicted growth at its peak, without hitting the target.
The thesis — published January 14, 2026
Thermo Fisher should get more positive attention soon because it announced a partnership with NVIDIA to add AI to lab work and said reshoring is bringing new contracts. That makes the stock worth buying on a small pullback in the next 0-3 months. Big defensive stocks can underperform if riskier stocks rally, so be realistic.
Primary drivers
- NVIDIA deal helps add AI to lab processes
- Reshoring is creating new contract opportunities
- Strong healthcare tools business draws conservative buyers
- Pullback entry gives a clear, limited downside
How it played out
TMO: target was not reached
Lyra published TMO at $616.89 on January 14, 2026, with a short-term window through April 14, 2026. The thesis expected 14% growth toward $703.25. It pointed to the NVIDIA partnership adding artificial intelligence to lab work, reshoring contract opportunities, a defensive healthcare tools business, and a pullback entry with limited downside.
Inside the window, TMO peaked at $643.99 on January 22, 2026, with a 4.4% gain. That stayed below the target. It never got there. By April 14, 2026, the stock ended at $514.23. The thesis partially played out early, but it missed the target and finished below the publication price.
Prices are shown split- and dividend-adjusted, matching what public charts show today.
Share this receipt
A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.
Read the next call before it closes.
This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.